NHLBI Payline FY2026: No Cutoff, R01 Odds and Data
Updated 7 official sources
Quick Answer: NHLBI has no payline in FY2026. Its funding policy says it "does not have a 'payline' or strict cutoff in scores that it will fund." According to NIH's Data Book, NHLBI funded 14.6% of new R01 applications in FY2025 (596 of 4,094), down from 17.5% in FY2024.
Full answer and how we checked it
A Grantsights pull of NIH RePORTER found 585 new NHLBI R01 and R37 awards in FY2026, against 599 in FY2025.
This guide is for: heart, lung, blood and sleep investigators who searched for an NHLBI payline, have a score in hand or coming, and need to know what replaced the cutoff and how often NHLBI actually funds R01 applications.
Data note: Policy text comes from NHLBI's FY2026 funding policies page on grants.nih.gov, read October 1, 2026. Success rates come from NIH Data Book table 206 (data last updated February 18, 2026) and table 217. FY2024-FY2026 award counts, project lengths and award-notice months come from a Grantsights pull of the NIH RePORTER API on October 1, 2026 (administering institute NHLBI, activity codes R01 and R37, award types 1 and 2). The same query can be rerun in NIH RePORTER.
In this guide
- NHLBI Payline Status: No Cutoff in FY2026
- NHLBI R01 Success Rates Since FY2019
- The Four-Year R01 Rule in the Award Record
- Budget Size and Award Size Since FY2024
- ESI Renewals and the R56 Fallback
- When NHLBI Awards Arrive
- NHLBI Odds Beyond the R01, FY2025
- What NHLBI's Policy Page Doesn't Tell You
- Apply, Resubmit, or Re-Scope: A Decision Table
- Sources
- Related Guides
NHLBI's figures sit beside every other institute's in the NIH and NSF funding odds tracker, which also summarizes each institute's FY2026 funding policy.
Searches for "NHLBI payline" usually come from someone holding a percentile and wanting a yes or no. NHLBI won't give that number, and older payline figures floating online shouldn't stand in for it. What's left is a decision framework, the institute's funding odds, and an award record that shows how the policy plays out.
From Manusights, our sister product
Applying for an R01 or R21? Manusights offers an AI critique of your application against NIH's published review criteria: $149 for a new R01 or R21, $199 for a resubmission. Back within 3 business days of your upload.
Order a grant reviewNHLBI Payline Status: No Cutoff in FY2026
According to the NHLBI FY2026 funding policies (opens in a new tab), the institute supports "a broad research portfolio and therefore does not have a 'payline' or strict cutoff in scores that it will fund." It lists 6 decision factors:
| NHLBI decision factor (FY2026 policy) | What it means for a scored application |
|---|---|
| Scientific and technical merit, informed by peer review | Your score and summary statement still lead |
| National Heart, Lung, and Blood Advisory Council recommendations | Council round timing matters |
| Relevance to NHLBI strategic and agency priorities | Fit with the strategic vision can lift or sink a borderline score |
| Overall portfolio balance | A crowded topic is harder to fund at the same score |
| Development of the biomedical workforce | Career stage can count in your favor |
| Potential for high public health impact | Significance has to be explicit, not implied |
The same page says NHLBI won't provide inflationary increases on future-year commitments for competing or non-competing research grants. Budget the out-years flat.
Two caveats keep this current. First, NHLBI's page notes that NIH is operating under a continuing resolution (NOT-OD-26-131 (opens in a new tab)), which runs through December 11, 2026 at the FY2026 level, so FY2027 terms may change. Second, the NIH paylines guide explains why a percentile still carries information even when no cutoff exists.
Get research funding calls by email
About once a week, we email open research funding calls with a real deadline, from federal agencies such as NIH and NSF, picked for research institutions. One click to unsubscribe.
No spam. Unsubscribe anytime.
NHLBI R01 Success Rates Since FY2019
If there's no payline, the success rate is the best public measure of competition. NIH's success-rate tables (opens in a new tab) give NHLBI's numbers by year.
| Fiscal year | R01 and R37 applications | Awards | Success rate | Average funding per award |
|---|---|---|---|---|
| FY2019 | 3,328 | 745 | 22.4% | $600,518 |
| FY2021 | 3,588 | 718 | 20.0% | $618,961 |
| FY2023 | 3,598 | 714 | 19.8% | $661,432 |
| FY2024 | 3,914 | 728 | 18.6% | $677,537 |
| FY2025 | 4,476 | 693 | 15.5% | $741,247 |
Source: NIH Data Book table 206, all competing types summed by Grantsights. The FY2025 drop came mostly from the denominator. Applications rose by 562 in one year while awards fell by 35. Across every research project grant, NIH's table 217 shows NHLBI at 16.6% in FY2025 (889 of 5,341), down from 19.7%.
New and renewal applications tell different stories:
| NHLBI R01 only | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| New applications / awards | 3,286 / 614 | 3,571 / 624 | 4,094 / 596 |
| New success rate | 18.7% | 17.5% | 14.6% |
| Renewal applications / awards | 312 / 100 | 342 / 103 | 382 / 97 |
| Renewal success rate | 32.1% | 30.1% | 25.4% |
NHLBI's combined R01 and R37 rate of 15.5% stayed above the NIH-wide R01-equivalent rate, which NIH reported at 13.0% for FY2025. That's a modest edge, not a reason to aim an application at NHLBI when the science belongs elsewhere.
The Four-Year R01 Rule in the Award Record
NHLBI's policy says it will fund approved investigator-initiated R01s "for up to four years." Exceptions cover Early Stage Investigators and clinical studies or trials whose accrual and follow-up need more time. Grantsights checked project lengths for every new NHLBI R01 and R37 award in RePORTER.
| New NHLBI R01/R37 awards | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
| New award records | 631 | 599 | 585 |
| Four-year project period | 393 | 362 | 294 |
| Five-year project period | 212 | 195 | 209 |
| Two-year project period | rare (under 7) | 14 | 78 |
| Multi-year funded (one budget period over 13 months) | 0 | 21 | 93 |
Grantsights analysis of the award record shows the four-year rule clearly: about 62% of new awards in FY2024 were four-year projects. Under the policy, five-year awards are the exception path for ESIs and for clinical studies. FY2026 added something new. 93 new awards were multi-year funded, paid up front instead of year by year, and 78 carried two-year project periods. The award record shows these shifts but not their reasons, so ask your program officer how they apply to your mechanism.
The planning point is plain. Unless you're an ESI or running a trial that needs five years, write the aims and timeline so the project works in four. A five-year plan cut to four at award time loses a year of work, not just a year of money.
Budget Size and Award Size Since FY2024
Grantsights also read first-year direct costs on new awards paid one budget year at a time:
| New NHLBI R01/R37 awards, single-year budgets | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
| Median total award (direct plus indirect) | $688,146 | $710,671 | $754,842 |
| Median first-year direct cost | $459,944 | $471,439 | $497,453 |
| Awards under $500,000 direct | 509 of 631 | 448 of 577 | 325 of 492 |
The median direct cost crept up to just below $500,000. That threshold matters at NHLBI because the policy offers R56 interim funding only to R01 applications requesting less than $500,000 in direct costs per year. An application above it gives up that fallback.
ESI Renewals and the R56 Fallback
NHLBI's FY2026 policy has a special rule for investigators whose first R01 was funded as an NHLBI ESI award. When the PI renews that award (Type 2) or submits a new Type 1 R01, NHLBI will fund all council-recommended years if three conditions hold:
- The original award was funded as an NHLBI ESI application and is in its last project year or within two fiscal years after it.
- The PI hasn't held a disqualifying major award, such as another R01 or a K02.
- The application comes from a domestic institution, and every PI on a multiple-PI application qualifies.
NHLBI staff identify eligible applications themselves; NIH's system doesn't flag them. If you think you qualify, say so to the program officer early.
The R56 is a weaker safety net than it used to be. NIH's table 206 shows 42 NHLBI R56 awards in FY2024 and just 1 in FY2025. The policy still allows them "pending the availability of funds," but one award in a year is not a plan. The NHLBI Emerging Investigator Award guide covers the R35 route that some early-career investigators use instead.
When NHLBI Awards Arrive
Without a payline, timing becomes the other unknown. RePORTER's award notice dates for FY2026 new NHLBI R01 and R37 awards cluster at the end of the fiscal year:
| Month (FY2026) | New award notices |
|---|---|
| June 2026 | 91 |
| July 2026 | 135 |
| August 2026 | 207 |
| September 2026 | 110 |
FY2025 followed the same shape, with 150 notices in August and 136 in September. An application reviewed in the fall can sit unresolved into the summer. Prepare the A1 while you wait instead of holding it for a decision that may not come until August.
NHLBI Odds Beyond the R01, FY2025
A payline search often comes from someone choosing among NHLBI mechanisms, not only R01s. Grantsights compared NHLBI's FY2025 rates across NIH Data Book tables 203, 204 and 206:
| NHLBI mechanism, FY2025 | Awards / applications | Success rate |
|---|---|---|
| R01, new | 596 / 4,094 | 14.6% |
| R01, competing renewal | 97 / 382 | 25.4% |
| R21 | 55 / 289 | 19.0% |
| K01 | 22 / 63 | 34.9% |
| K08 | 49 / 110 | 44.5% |
| K23 | 56 / 166 | 33.7% |
| K99 | 40 / 139 | 28.8% |
| F31 | 115 / 335 | 34.3% |
| F32 | 49 / 140 | 35.0% |
For example, NHLBI received 4,094 new R01 applications in FY2025 but only 110 K08 applications, and it funded the K08s at three times the R01 rate. The honest takeaway for a clinician-scientist without independent funding: a K08 or K23 at NHLBI is often a better first route than an R01, provided the mentoring plan is real. The K award success-rate page compares those odds across institutes, and the F31 page covers trainees.
What NHLBI's Policy Page Doesn't Tell You
| Source | What it gives you | What it doesn't |
|---|---|---|
| NHLBI FY2026 policy page | Decision factors, four-year rule, ESI and R56 rules | Any percentile at which awards become likely |
| NIH Data Book tables 206 and 217 | Applications, awards and success rates by year | Rates by percentile band or study section |
| NIH RePORTER | Award sizes, project lengths, notice dates | Which scored applications went unfunded |
| Older payline figures online | A sense of historical bars | Anything about FY2026 decisions |
The common mistake is anchoring on an old payline number from a forum or a department slide. NHLBI's FY2026 page uses no cutoff, so a remembered number can make a 20th-percentile score feel safe or hopeless when neither is true.
Apply, Resubmit, or Re-Scope: A Decision Table
| Your situation | Best next action |
|---|---|
| Scored, no word yet | Ask the program officer once whether it's under consideration; start the A1 outline now |
| New R01 written as five years, PI not an ESI | Re-scope to four years before submission |
| Budget near $500,000 direct per year | Decide deliberately; staying under keeps the R56 fallback open |
| ESI-funded R01 nearing its end | Raise the special renewal rule with the program officer |
| Unfunded A1 | Consider whether the aims fit NHLBI priorities or belong at another institute |
For the resubmission itself, use the summary statement guide and the resubmission guide. To compare institutes, see the NIAID R01 success-rate page and the NIDDK payline page. To find other cardiovascular and pulmonary funding, use Grantsights grant search.
Sources
- NHLBI FY2026 funding policies and considerations (opens in a new tab)
- NIH Data Book success-rate tables (opens in a new tab) (tables 206 and 217)
- NIH, Fiscal Year 2025 By the Numbers (opens in a new tab)
- NOT-OD-26-131, NIH Operates Under a Continuing Resolution (opens in a new tab)
- NIH Early Stage Investigator policies (opens in a new tab)
- NIH RePORTER (opens in a new tab) and the RePORTER API (opens in a new tab)
Related Guides
Frequently Asked Questions
What is the NHLBI payline for 2026?
There isn't one. NHLBI's FY2026 funding policy says the institute 'does not have a payline or strict cutoff in scores that it will fund.' Decisions weigh peer review, advisory council recommendations, strategic priorities, portfolio balance, workforce development and public health impact.
What share of NHLBI R01 applications get funded?
NIH Data Book table 206 shows NHLBI funded 596 of 4,094 new R01 applications in FY2025 (14.6%) and 97 of 382 competing renewals (25.4%). Counting R01 and R37 together across all competing types, the FY2025 rate was 15.5%, down from 18.6% in FY2024.
How long are NHLBI R01 awards?
NHLBI's FY2026 policy funds approved investigator-initiated R01s for up to four years, with exceptions for Early Stage Investigators and for clinical studies and trials that need longer. In a Grantsights pull of NIH RePORTER, 294 of 585 new FY2026 NHLBI R01 and R37 awards had four-year project periods and 209 had five-year periods.
Does a good percentile still matter at NHLBI without a payline?
Yes. Peer review is the first factor NHLBI lists. Without a published cutoff, though, no percentile guarantees or rules out an award, so ask the program officer whether the application is under consideration and plan a resubmission in parallel.
Does NHLBI still give R56 bridge awards?
The policy says NHLBI may use R56 awards, pending funds, for competing R01 applications requesting under $500,000 in direct costs per year. NIH's success-rate table shows 42 NHLBI R56 awards in FY2024 and 1 in FY2025, so don't plan around one.
Last updated October 1, 2026. Published by Grantsights from public sources. See our editorial policy, how we build and check guides, corrections and how we make money.
Related Guides
NCI Payline 2026: No Cutoff, Budget Cuts, R01 Odds
NCI dropped paylines for FY2026 and cuts new R01 budgets by 6.5% to 17%. NIH tables show NCI funded 6.9% of new R01 applications in FY2025.
NEI Payline 2026: No Cutoff and a 12.8% New R01 Rate
NEI publishes no FY2026 payline or score cutoff. Its new R01 success rate fell from 23.6% to 12.8% in FY2025, while renewals held at 32.6%. See the data.
NIA Payline 2026: No Cutoff, 5.0% New R01 Odds
NIA has published no payline since FY2024, when general R01s funded to the 16th percentile. Its new R01 success rate fell to 5.0% in FY2025. See the data.
NIBIB Payline 2026: No Cutoff and a 16.1% New R01 Rate
NIBIB has no FY2026 payline. It cuts parent R01 budgets 10% to 20% and caps them at 4 years. Its new R01 success rate was 16.1% in FY2025. See the data.
NICHD Payline 2026: No Cutoff, 14.1% New R01 Odds
NICHD publishes no payline. It funded 14.1% of new R01s in FY2025 and cuts new R01 budgets 14% on average. See the rules and five years of odds.
NIDA Payline 2026: No Cutoff, 11.5% New R01 Odds
NIDA has no payline. It funded 11.5% of new R01s in FY2025 and caps renewal growth at 10% without strong justification. See NIDA's rules and odds.